Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.53 |
| ▸ | BCHE | P06276 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | CHKA | P35790 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127774 | 0.77 | ACHE (0.85) | ACHEBCHE | |
| Bromide SCHEMBL3601825 | 0.75 | ACHE (0.89) | ACHEBCHE | |
| Hydrochloric Acid SCHEMBL8870693 | 0.75 | ACHE (0.81) | ACHEBCHELMNA | |
| SCHEMBL7827657 | 0.74 | ACHE (0.53) | ACHEBCHELMNAALDH1A1SMN1; SMN2 | |
| Bromide SCHEMBL7991325 | 0.73 | ACHE (0.56) | ACHEBCHELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL16492221 | 0.73 | CYP1A2 (0.54) | ACHEBCHELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL17790285 | 0.72 | ACHE (0.59) | ACHEBCHELMNACYP1A2CYP2D6 | |
| Bromide SCHEMBL17783238 | 0.71 | ACHE (0.61) | ACHEBCHELMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL8870095 | 0.71 | ACHE (0.61) | ACHEBCHELMNA | |
| SCHEMBL10692064 | 0.69 | CHKA (0.57) | ACHELMNAALDH1A1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476297-B2 | TRP-M8 receptor ligands and their use in treatments | AMGEN INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20100261728-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2010-10-14 | — | — | US | disclosed |
| WO-2009073203-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261728-A1 | TRP-M8 RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPM8, TRPV2 | ACHE 576/4885BCHE 2180/4885LMNA 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.